Know Cancer

or
forgot password

STAT3 in T Cells: At The Crossroads of Inflammation and Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Cutaneous T Cell Lymphoma

Thank you

Trial Information

STAT3 in T Cells: At The Crossroads of Inflammation and Cancer


Inclusion Criteria:



- Adult patients with CTCL that are starting new form of treatment and adult patients
with benign dermatoses.

Exclusion Criteria:

- patients with lymphomas other than CTCL or leukemia

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Measure the levels of Th 17 cytokines namely Il-17 and Il-22 in CTCL

Outcome Time Frame:

2 -3 years

Safety Issue:

No

Principal Investigator

Sergei Koralov, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

NYU School of Medicine

Authority:

United States: Institutional Review Board

Study ID:

11-01293

NCT ID:

NCT01663571

Start Date:

May 2012

Completion Date:

Related Keywords:

  • Cutaneous T Cell Lymphoma
  • Inflammation
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous

Name

Location

NYU Langone Medical CenterNew York, New York  10016